(Q46233987)

20 December 2017

title

The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients (English)

1 reference

20 December 2017

author name string

S M Flechner

1

1 reference

20 December 2017

M Glyda

2

1 reference

20 December 2017

S Cockfield

3

1 reference

20 December 2017

J Grinyó

4

1 reference

20 December 2017

Ch Legendre

5

1 reference

20 December 2017

G Russ

6

1 reference

20 December 2017

S Steinberg

7

1 reference

20 December 2017

K M Wissing

8

1 reference

20 December 2017

S S Tai

9

1 reference

20 December 2017

language of work or name

English

0 references

publication date

10 June 2011

1 reference

20 December 2017

American Journal of Transplantation

published in

1 reference

20 December 2017

volume

11

1 reference

20 December 2017

page(s)

1633-1644

1 reference

20 December 2017

issue

8

1 reference

20 December 2017

The natural history of chronic allograft nephropathy

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Sirolimus is associated with new-onset diabetes in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03573.X

10.1111/J.1600-6143.2011.03573.X

21 January 2018

Identifiers

DOI

1 reference

20 December 2017

PubMed ID

21668635

1 reference

20 December 2017